Navigating the Orphan Drug Act and FDA Designation

This guide outlines the Orphan Drug Act (ODA) and its impact on the development of treatments for rare diseases in the United States. Enacted in 1983, the ODA incentivizes pharmaceutical companies to create therapies for conditions affecting fewer than 200,000 people. It provides various benefits such as tax credits, market exclusivity, and waived FDA fees, which have significantly increased the number of approved orphan drugs. The document details the history of rare disease drug development, highlighting the FDA's evolving role and the challenges faced in this sector, including regulatory hurdles and high development costs. It also explains the process for filing an Orphan Drug Designation request, including the necessary components and criteria for FDA evaluation. Furthermore, the guide discusses the advantages and challenges associated with orphan drug designation, emphasizing the importance of understanding the regulatory landscape to successfully bring rare disease treatments to market.